Medizinische Universität Graz - Research portal
Selected Publication:
Chopra, R; Eaton, JD; Grassi, A; Potter, M; Shaw, B; Salat, C; Neumeister, P; Finazzi, G; Iacobelli, M; Bowyer, K; Prentice, HG; Barbui, T.
Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study.
Br J Haematol. 2000; 111(4):1122-1129
Doi: 10.1046%2Fj.1365-2141.2000.02475.x
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Neumeister Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Severe hepatic veno-occlusive disease (VOD) is a recognized complication of autologous and allogeneic stem cell transplantation (SCT) that is often fatal. Defibrotide (DF) is a polydeoxyribonucleotide that has been found to have anti-thrombotic, anti-ischaemic and thrombolytic properties without causing significant anticoagulation. Preliminary studies have demonstrated activity for DF in the treatment of VOD, with minimal associated toxicity. In the present study, 40 patients who fulfilled established criteria for VOD were treated with DF on compassionate grounds in 19 European centres; 28 patients met risk criteria predicting progression of VOD and fatality or had evidence of multiorgan failure (MOF), and were defined as 'poor-risk'. DF was commenced intravenously at a median of 14 d (range, -2 d to 53 d) post SCT at doses ranging from 10 to 40 mg/kg. The median duration of therapy was 18 d (range, 2--71 d). Twenty-two patients showed a complete response (CR) (bilirubin < 34.2 micromol/l and resolution of signs/symptoms of VOD and end-organ dysfunction) [CR = 55%, confidence interval (CI) 40--70%] and 17 patients (43%) are alive beyond d +100. Ten poor-risk patients showed a complete response (CR = 36%, CI 21--51%). These results demonstrate that DF is an active treatment for VOD following SCT and a randomized trial is now underway in order to further evaluate its role.
- Find related publications in this database (using NLM MeSH Indexing)
- Acute Disease -
- Adolescent -
- Adult -
- Bilirubin - analysis
- Breast Neoplasms - drug therapy
- Child - drug therapy
- Child, Preschool - drug therapy
- Female - drug therapy
- Fibrinolytic Agents - therapeutic use
- Hematopoietic Stem Cell Transplantation - therapeutic use
- Hepatic Veno-Occlusive Disease - blood
- Hodgkin Disease - drug therapy
- Humans - drug therapy
- Infant - drug therapy
- Leukemia, Lymphocytic, Acute - drug therapy
- Leukemia, Myeloid - drug therapy
- Male - drug therapy
- Middle Aged - drug therapy
- Multiple Myeloma - drug therapy
- Polydeoxyribonucleotides - therapeutic use
- Postoperative Complications - drug therapy
- Treatment Outcome - drug therapy
- Find related publications in this database (Keywords)
- defibrotide
- veno-occlusive disease
- stem cell transplantation
- multiorgan failure
- DNA aptamer